Monoclonal Antibody Therapy Market By Source (Human, Recombinant, Humanized, Chimeric and Other Sources), Application (Hematological Disorders, Cancer Treatment, Diagnostic Test, Autoimmune Diseases, Analytical And Chemical Uses and Other Applications) and End User (Clinic, Research Laboratories, Hospitals and Other End Users) - Global Industry Analysis And Forecast To 2027
Published On : September 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC091269
Industry Outlook
Monoclonal Antibody (moAb or mAb), are antibodies composed of siliar immune cells that are clone of single rare primary cell. Monoclonal Antibody has monovalent affinity i.e. it forms bond with similar epitope. Monoclonal Antibody Therapy is type of immunotherapy that uses monoclonal antibodies (mAb); this treatment is used for stimulating the immune system of patient for attacking cells or proteins. It is possible to produce Monoclonal Antibody that targets a specific cell surface. Research is going on for developing antibodies that can fight diseases like arthritis, Alzheimer's disease, Ebola, etc. Therefore, the Monoclonal Antibody Therapy Market is anticipated to expand and has tremendous scope during the forecast period. The global Monoclonal Antibody Therapy Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Monoclonal Antibody Therapy Market is based on segment, by Source the market is segmented into Human, Recombinant, Humanized, Chimeric and Other Sources, by Application the market is segmented into Hematological Disorders, Cancer Treatment, Diagnostic Test, Autoimmune Diseases, Analytical And Chemical Uses and Other Applications, and by End User the market is segmented into Clinic, Research Laboratories, Hospitals and Other End Users.
- Monoclonal Antibody Therapy Market, By Source
- Human
- Recombinant
- Humanized
- Chimeric
- Other Sources
- Monoclonal Antibody Therapy Market, By Application
- Hematological Disorders
- Cancer Treatment
- Diagnostic Test
- Autoimmune Diseases
- Analytical And Chemical Uses
- Other Applications
- Monoclonal Antibody Therapy Market, By End User
- Clinic
- Research Laboratories
- Hospitals
- Other End Users
Regional Insights
On a global front, the Monoclonal Antibody Therapy Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA).
Monoclonal Antibody Therapy Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Pfizer Inc., Bristol – Myers Squibb Company, Sigma-Aldrich Co. LLC, F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson, Amgen Inc., GlaxoSmithKline Plc., Novartis AG, Bayer AG, Merck KGaA, Biogen Inc., GenScript and Sanofi. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Pfizer Inc.
- Bristol – Myers Squibb Company
- Sigma-Aldrich Co. LLC
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- GlaxoSmithKline Plc.
- Novartis AG
- Bayer AG
- Merck KGaA
- Biogen Inc.
- GenScript
- Sanofi
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Monoclonal Antibody Therapy Market, By Source, Estimates and Forecast, 2017-2027 ($Million)
o Human
o Recombinant
o Humanized
o Chimeric
o Other Sources
o Monoclonal Antibody Therapy Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Hematological Disorders
o Cancer Treatment
o Diagnostic Test
o Autoimmune Diseases
o Analytical And Chemical Uses
o Other Applications
o Monoclonal Antibody Therapy Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Clinic
o Research Laboratories
o Hospitals
o Other End Users
Monoclonal Antibody Therapy Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Monoclonal Antibody Therapy Market, By Country
o U.S. Monoclonal Antibody Therapy Market
o Canada Monoclonal Antibody Therapy Market
o Mexico Monoclonal Antibody Therapy Market
o Europe
§ Europe Monoclonal Antibody Therapy Market, By Country
o Germany Monoclonal Antibody Therapy Market
o UK Monoclonal Antibody Therapy Market
o France Monoclonal Antibody Therapy Market
o Russia Monoclonal Antibody Therapy Market
o Italy Monoclonal Antibody Therapy Market
o Rest of Europe Monoclonal Antibody Therapy Market
o Asia-Pacific
§ Asia-Pacific Monoclonal Antibody Therapy Market, By Country
o China Monoclonal Antibody Therapy Market
o Japan Monoclonal Antibody Therapy Market
o South Korea Monoclonal Antibody Therapy Market
o India Monoclonal Antibody Therapy Market
o Southeast Asia Monoclonal Antibody Therapy Market
o Rest of Asia-Pacific Monoclonal Antibody Therapy Market
o South America
§ South America Monoclonal Antibody Therapy Market, By Country
o Brazil Monoclonal Antibody Therapy Market
o Argentina Monoclonal Antibody Therapy Market
o Columbia Monoclonal Antibody Therapy Market
o Rest of South America Monoclonal Antibody Therapy Market
o Middle East and Africa
§ Middle East and Africa Monoclonal Antibody Therapy Market, By Country
o Saudi Arabia Monoclonal Antibody Therapy Market
o UAE Monoclonal Antibody Therapy Market
o Egypt Monoclonal Antibody Therapy Market
o Nigeria Monoclonal Antibody Therapy Market
o South Africa Monoclonal Antibody Therapy Market
o Rest of MEA Monoclonal Antibody Therapy Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Monoclonal Antibody Therapy Market, By Source
5.1. Introduction
5.2. Global Monoclonal Antibody Therapy Revenue and Market Share by Source (2017-2027)
5.2.1. Global Monoclonal Antibody Therapy Revenue and Revenue Share by Source (2017-2027)
5.3. Human
5.3.1. Global Human Revenue and Growth Rate (2017-2027)
5.4. Recombinant
5.4.1. Global Recombinant Revenue and Growth Rate (2017-2027)
5.5. Humanized
5.5.1. Global Humanized Revenue and Growth Rate (2017-2027)
5.6. Chimeric
5.6.1. Global Chimeric Revenue and Growth Rate (2017-2027)
5.7. Other Sources
5.7.1. Global Other Sources Revenue and Growth Rate (2017-2027)
6. Monoclonal Antibody Therapy Market, By Application
6.1. Introduction
6.2. Global Monoclonal Antibody Therapy Revenue and Market Share by Application (2017-2027)
6.2.1. Global Monoclonal Antibody Therapy Revenue and Revenue Share by Application (2017-2027)
6.3. Hematological Disorders
6.3.1. Global Hematological Disorders Revenue and Growth Rate (2017-2027)
6.4. Cancer Treatment
6.4.1. Global Cancer Treatment Revenue and Growth Rate (2017-2027)
6.5. Diagnostic Test
6.5.1. Global Diagnostic Test Revenue and Growth Rate (2017-2027)
6.6. Autoimmune Diseases
6.6.1. Global Autoimmune Diseases Revenue and Growth Rate (2017-2027)
6.7. Analytical And Chemical Uses
6.7.1. Global Analytical And Chemical Uses Revenue and Growth Rate (2017-2027)
6.8. Other Applications
6.8.1. Global Other Applications Revenue and Growth Rate (2017-2027)
7. Monoclonal Antibody Therapy Market, By End User
7.1. Introduction
7.2. Global Monoclonal Antibody Therapy Revenue and Market Share by End User (2017-2027)
7.2.1. Global Monoclonal Antibody Therapy Revenue and Revenue Share by End User (2017-2027)
7.3. Clinic
7.3.1. Global Clinic Revenue and Growth Rate (2017-2027)
7.4. Research Laboratories
7.4.1. Global Research Laboratories Revenue and Growth Rate (2017-2027)
7.5. Hospitals
7.5.1. Global Hospitals Revenue and Growth Rate (2017-2027)
7.6. Other End Users
7.6.1. Global Other End Users Revenue and Growth Rate (2017-2027)
8. Monoclonal Antibody Therapy Market, By Region
8.1. Introduction
8.2. Global Monoclonal Antibody Therapy Revenue and Market Share by Regions
8.2.1. Global Monoclonal Antibody Therapy Revenue by Regions (2017-2027)
8.3. North America Monoclonal Antibody Therapy by Countries
8.3.1. North America Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2027)
8.3.2. North America Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Monoclonal Antibody Therapy by Countries
8.4.1. Europe Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2027)
8.4.2. Europe Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Monoclonal Antibody Therapy by Countries
8.5.1. Asia-Pacific Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Monoclonal Antibody Therapy by Countries
8.6.1. South America Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2027)
8.6.2. South America Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Monoclonal Antibody Therapy by Countries
8.7.1. Middle East and Africa Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Pfizer Inc.
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Bristol – Myers Squibb Company
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Sigma-Aldrich Co. LLC
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. F. Hoffmann-La Roche Ltd.
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. AbbVie Inc.
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Johnson & Johnson
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. Amgen Inc.
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
9.8. GlaxoSmithKline Plc.
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Revenue and Market Share
9.9. Novartis AG
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Revenue and Market Share
9.10. Bayer AG
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Revenue and Market Share
9.11. Merck KGaA
9.11.1. Business Overview
9.11.2. Service Portfolio
9.11.3. Strategic Developments
9.11.4. Revenue and Market Share
9.12. Biogen Inc.
9.12.1. Business Overview
9.12.2. Service Portfolio
9.12.3. Strategic Developments
9.12.4. Revenue and Market Share
9.13. GenScript
9.13.1. Business Overview
9.13.2. Service Portfolio
9.13.3. Strategic Developments
9.13.4. Revenue and Market Share
9.14. Sanofi
9.14.1. Business Overview
9.14.2. Service Portfolio
9.14.3. Strategic Developments
9.14.4. Revenue and Market Share
10. Global Monoclonal Antibody Therapy Market Competition, by Manufacturer
10.1. Global Monoclonal Antibody Therapy Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Monoclonal Antibody Therapy Price By Region (2017-2017)
10.3. Top 5 Monoclonal Antibody Therapy Manufacturer Market Share
10.4. Market Competition Trend
11. Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.1. Global Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Monoclonal Antibody Therapy Market Forecast by Regions (2017-2027)
11.2.1. North America Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.1.1. United States Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.1.2. Canada Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.1.3. Mexico Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2. Europe Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2.1. Germany Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2.2. France Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2.3. UK Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2.4. Russia Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2.5. Italy Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3. Asia-Pacific Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3.1. China Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3.2. Japan Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3.3. Korea Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3.4. India Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.4. South America Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.4.1. Brazil Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.4.2. Argentina Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.4.3. Columbia Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.4.4. Rest of South America Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5. Middle East and Africa Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.3. Egypt Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.4. Nigeria Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.5. South Africa Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.6. Turkey Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Monoclonal Antibody Therapy Market Forecast (2017-2027)
11.3. Monoclonal Antibody Therapy Market Forecast by Source (2017-2027)
11.3.1. Monoclonal Antibody Therapy Forecast by Source (2017-2027)
11.3.2. Monoclonal Antibody Therapy Market Share Forecast by Source (2017-2027)
11.4. Monoclonal Antibody Therapy Market Forecast by Application (2017-2027)
11.4.1. Monoclonal Antibody Therapy Forecast by Application (2017-2027)
11.4.2. Monoclonal Antibody Therapy Market Share Forecast by Application (2017-2027)
11.5. Monoclonal Antibody Therapy Market Forecast by End User (2017-2027)
11.5.1. Monoclonal Antibody Therapy Forecast by End User (2017-2027)
11.5.2. Monoclonal Antibody Therapy Market Share Forecast by End User (2017-2027)
List of Tables
12. List of Tables and Figures
Figure United States Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Monoclonal Antibody Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Monoclonal Antibody Therapy Revenue and Revenue Share by Source (2017-2018)
Figure Global Human Revenue and Growth Rate (2017-2018)
Figure Global Recombinant Revenue and Growth Rate (2017-2018)
Figure Global Humanized Revenue and Growth Rate (2017-2018)
Figure Global Chimeric Revenue and Growth Rate (2017-2018)
Figure Global Other Sources Revenue and Growth Rate (2017-2018)
Table Global Monoclonal Antibody Therapy Revenue and Revenue Share by Application (2017-2018)
Figure Global Hematological Disorders Revenue and Growth Rate (2017-2018)
Figure Global Cancer Treatment Revenue and Growth Rate (2017-2018)
Figure Global Diagnostic Test Revenue and Growth Rate (2017-2018)
Figure Global Autoimmune Diseases Revenue and Growth Rate (2017-2018)
Figure Global Analytical And Chemical Uses Revenue and Growth Rate (2017-2018)
Figure Global Other Applications Revenue and Growth Rate (2017-2018)
Table Global Monoclonal Antibody Therapy Revenue and Revenue Share by End User (2017-2018)
Figure Global Clinic Revenue and Growth Rate (2017-2018)
Figure Global Research Laboratories Revenue and Growth Rate (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Other End Users Revenue and Growth Rate (2017-2018)
Table Global Monoclonal Antibody Therapy Revenue by Regions (2017-2018)
Figure North America Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure North America Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2018)
Figure North America Monoclonal Antibody Therapy by Countries (2017-2018)
Figure North America Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2018)
Figure United States Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure United States Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Canada Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Mexico Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Europe Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2018)
Figure Europe Monoclonal Antibody Therapy by Countries (2017-2018)
Figure Europe Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2018)
Figure Germany Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Germany Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure France Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure UK Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Russia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Italy Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Rest of Europe Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Asia-Pacific Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Monoclonal Antibody Therapy by Countries (2017-2018)
Figure Asia-Pacific Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2018)
Figure China Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure China Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Japan Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Korea Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure India Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Southeast Asia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure South America Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2018)
Figure South America Monoclonal Antibody Therapy by Countries (2017-2018)
Figure South America Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Brazil Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Argentina Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Columbia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Rest of South America Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Middle East and Africa Monoclonal Antibody Therapy Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Monoclonal Antibody Therapy by Countries (2017-2018)
Figure Middle East and Africa Monoclonal Antibody Therapy Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Saudi Arabia Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure United Arab Emirates Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Egypt Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Nigeria Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure South Africa Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Turkey Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Monoclonal Antibody Therapy Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Table Pfizer Inc. Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol – Myers Squibb Company Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sigma-Aldrich Co. LLC Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann-La Roche Ltd. Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AbbVie Inc. Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Johnson & Johnson Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Inc. Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GlaxoSmithKline Plc. Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer AG Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck KGaA Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biogen Inc. Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GenScript Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Monoclonal Antibody Therapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Monoclonal Antibody Therapy Market Share by Manufacturer
Figure Global Monoclonal Antibody Therapy Revenue and Market Share by Manufacturer
Table Global Monoclonal Antibody Therapy Price by Region (2017-2017)
Figure Top 5 Monoclonal Antibody Therapy Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Monoclonal Antibody Therapy Revenue (Millions USD) and Growth Rate (2018-2025)
Table Monoclonal Antibody Therapy Market Forecast by Regions (2018-2025)
Figure North America Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure United States Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Canada Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Mexico Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Europe Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Germany Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure France Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure UK Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Russia Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Italy Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Rest of Europe Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Asia-Pacific Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure China Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Japan Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Korea Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure India Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Southeast Asia Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure South America Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Brazil Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Argentina Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Columbia Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Rest of South America Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Middle East and Africa Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Saudi Arabia Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure United Arab Emirates Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Egypt Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Nigeria Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure South Africa Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Turkey Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Monoclonal Antibody Therapy Market Forecast (2018-2025)
Figure Global Monoclonal Antibody Therapy Forecast by Source (2018-2025)
Figure Global Monoclonal Antibody Therapy Market Share Forecast by Source (2018-2025)
Figure Global Monoclonal Antibody Therapy Forecast by Source (2018-2025)
Figure Global Monoclonal Antibody Therapy Forecast by Application (2018-2025)
Figure Global Monoclonal Antibody Therapy Market Share Forecast by Application (2018-2025)
Figure Global Monoclonal Antibody Therapy Forecast by Application (2018-2025)
Figure Global Monoclonal Antibody Therapy Forecast by End User (2018-2025)
Figure Global Monoclonal Antibody Therapy Market Share Forecast by End User (2018-2025)
Figure Global Monoclonal Antibody Therapy Forecast by End User (2018-2025)
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|